| Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms A Prestipino, AJ Emhardt, K Aumann, D O’Sullivan, SP Gorantla, ... Science translational medicine 10 (429), eaam7729, 2018 | 206 | 2018 |
| International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study WR Sperr, M Kundi, I Alvarez-Twose, B van Anrooij, JNGO Elberink, ... The Lancet Haematology 6 (12), e638-e649, 2019 | 127 | 2019 |
| Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation S Hamarsheh, L Osswald, BS Saller, S Unger, D De Feo, JM Vinnakota, ... Nature communications 11 (1), 1659, 2020 | 109 | 2020 |
| MARS: mutation-adjusted risk score for advanced systemic mastocytosis M Jawhar, J Schwaab, I Álvarez-Twose, K Shoumariyeh, N Naumann, ... Journal of Clinical Oncology 37 (31), 2846, 2019 | 109 | 2019 |
| Metabolic reprogramming of donor T cells enhances graft-versus-leukemia effects in mice and humans FM Uhl, S Chen, D O’Sullivan, J Edwards-Hicks, G Richter, E Haring, ... Science translational medicine 12 (567), eabb8969, 2020 | 86 | 2020 |
| Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification J Trizuljak, WR Sperr, L Nekvindova, HO Elberink, KV Gleixner, A Gorska, ... Allergy 75 (8), 1927-1938, 2020 | 61 | 2020 |
| Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia N El Khawanky, A Hughes, W Yu, R Myburgh, T Matschulla, S Taromi, ... Nature Communications 12 (1), 1-20, 2021 | 56 | 2021 |
| The data registry of the European Competence Network on Mastocytosis (ECNM): set up, projects, and perspectives P Valent, JNGO Elberink, A Gorska, M Lange, R Zanotti, B van Anrooij, ... The Journal of Allergy and Clinical Immunology: In Practice 7 (1), 81-87, 2019 | 53 | 2019 |
| The data registry of the European Competence Network on Mastocytosis (ECNM): set up, projects, and perspectives P Valent, JNGO Elberink, A Gorska, M Lange, R Zanotti, B van Anrooij, ... The Journal of Allergy and Clinical Immunology: In Practice 7 (1), 81-87, 2019 | 53 | 2019 |
| Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany M Engelhardt, K Shoumariyeh, A Rösner, G Ihorst, F Biavasco, K Meckel, ... haematologica 105 (12), 2020 | 50 | 2020 |
| Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study JI Muñoz-González, I Álvarez-Twose, M Jara-Acevedo, R Zanotti, ... The Lancet Haematology 8 (3), e194-e204, 2021 | 45 | 2021 |
| Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry HC Kluin-Nelemans, A Reiter, A Illerhaus, B van Anrooij, K Hartmann, ... Leukemia 34 (4), 1090-1101, 2020 | 44 | 2020 |
| Covid‐19 in patients with hematological and solid cancers at a Comprehensive Cancer Center in Germany K Shoumariyeh, F Biavasco, G Ihorst, S Rieg, A Nieters, WV Kern, ... Cancer medicine 9 (22), 8412-8422, 2020 | 37 | 2020 |
| Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center Analysis R Hoefflin, A Lazarou, ME Hess, M Reiser, J Wehrle, P Metzger, AV Frey, ... Cancers 13 (5), 1151, 2021 | 36 | 2021 |
| Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis R Zanotti, M Bonifacio, G Lucchini, WR Sperr, L Scaffidi, B van Anrooij, ... Leukemia 36 (2), 516-524, 2022 | 34 | 2022 |
| KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis M Jawhar, K Döhner, S Kreil, J Schwaab, K Shoumariyeh, ... Leukemia 33 (5), 1124-1134, 2019 | 32 | 2019 |
| Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis HC Kluin-Nelemans, M Jawhar, A Reiter, B van Anrooij, J Gotlib, ... Theranostics 11 (1), 292, 2021 | 26 | 2021 |
| Community-driven development of a modified progression-free survival ratio for precision oncology A Mock, CE Heilig, S Kreutzfeldt, D Huebschmann, C Heining, E Schröck, ... ESMO open 4 (6), e000583, 2019 | 26 | 2019 |
| Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation JNHG Ho, D Schmidt, T Lowinus, J Ryoo, EP Dopfer, N Gonzalo Núñez, ... Blood, The Journal of the American Society of Hematology 140 (10), 1167-1181, 2022 | 24 | 2022 |
| Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry VE Kennedy, C Perkins, A Reiter, M Jawhar, J Lübke, HC Kluin-Nelemans, ... Blood advances 7 (9), 1713-1724, 2023 | 23 | 2023 |
Robert ZeiserProfessor of Medicine, University of FreiburgVerified email at uniklinik-freiburg.de
